Ann: AGM Presentations, page-10

Its a sad reflection of the majority of encouraged discussion on Hot Copper, that CYP's AGM only attracts commentary from MSB holders who have running battles with our Lordship on here (personally I own both stocks).

Only a fool would suggest CYP and MSB's future prospects not intertwined to a degree. Unlike MSB, CYP's future success from here is not reliant on GvHD approval from the FDA (and yes I am comfortable not critical that exposure in MSB, knowing the flood gates likely to open on C19 ARD's; degenerative disc disease; and congestive heart failure and the industry more generally in other applications).

I would remind you guys CYP is recruiting for what will be the largest phase III trial in MSc treatment of knee osteoarthritis in the Western world and is fully funded in that trial.

External trial funding admittedly can be both a blessing and a curse, as MSB so rudely found out with the NIH C19 ARD's trial - that the DSMB did not change the criteria on a rapidly changing standard of care in its control cohort was ridiculous - and CYP more recently in slow recruiting by UoSyd in its OA trial.